Zobrazeno 1 - 10
of 91
pro vyhledávání: '"John L. Magnani"'
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Neutrophils are essential to protect the host against invading pathogens but can promote disease progression in sickle cell disease (SCD) by becoming adherent to inflamed microvascular networks in peripheral tissue throughout the body. During the inf
Autor:
John L. Magnani, Ileana M. Cristea, Nandini Mondal, Corey Cheung, Sue Hwa Lin, Todd M. Greco, Hanqiu Zheng, Yibin Kang, Song Chang Lin, Yong Wei, Chiara Spadazzi, Robert Sackstein, Mark Esposito
Publikováno v:
Nature Cell Biology. 21:627-639
How disseminated tumour cells engage specific stromal components in distant organs for survival and outgrowth is a critical but poorly understood step of the metastatic cascade. Previous studies have demonstrated the importance of the epithelial–me
Autor:
William E. Fogler, John L. Magnani, Michael Andreeff, Yannan Jia, Kyung Hee Chang, Lauren B Ostermann, Qi Zhang, Weiguo Zhang, Marina Konopleva, Mahesh Basyal
Publikováno v:
Blood. 138:1171-1171
FLT3 inhibitors (FLT3i) have had transient success treating FLT3-mutant acute myeloid leukemia (AML) patients, especially those with FLT3 internal tandem duplication (ITD) mutations that account for one-third of adult AML cases (Daver et al., 2021).
Autor:
William E. Fogler, John L. Magnani, Mateusz Rytelewski, Malgorzata Anna Zal, Rodrigo Jacamo, Kyung Hee Chang, Tomasz Zal, Michael Andreeff
Publikováno v:
Blood. 136:14-15
BACKGROUND: Acute myelogenous leukemia (AML) cells that reside in bone marrow (BM) receive a great deal of protection from the cytotoxic effects of therapeutic agents. In contrast, the circulating leukemia cells are typically more chemosensitive comp
Autor:
Lauren B Ostermann, Yannan Jia, M. Anna Zal, Weiguo Zhang, Mahesh Basyal, Michael Andreeff, Tomasz Zal, William E. Fogler, John L. Magnani, Kyung Hee Chang
Publikováno v:
Blood. 136:17-18
Acute myelogenous leukemia (AML) is characterized by an accumulation of abnormal white blood cells. Internal tandem duplications in the fms-like tyrosine kinase 3 (FLT3-ITD) account for 30% of adult AML cases and confer poor prognosis (Nakao et al.,
Autor:
Shaji Kumar, Elena Ellert, M. Andrulis, C. Connolly, W. E. Fogler, Lucy Kirkham-McCarthy, S. C. Locatelli-Hoops, Alessandro Natoni, Cian McEllistrim, I. Oliva, Niamh Keane, T. A.G. Smith, Michael O'Dwyer, Marc-Steffen Raab, Alokkumar Jha, Siobhan Glavey, John L. Magnani
Publikováno v:
Leukemia
Multiple myeloma (MM) is characterized by the clonal expansion and metastatic spread of malignant plasma cells to multiple sites in the bone marrow (BM). Recently, we implicated the sialyltransferase ST3Gal-6, an enzyme critical to the generation of
Autor:
Feda Azab, Justin King, Abdel Kareem Azab, Daniel Kohnen, Ravi Vij, Barbara Muz, William E. Fogler, John L. Magnani, Mark A. Fiala, Theodore A.G. Smith
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-6 (2019)
Autor:
Kyung Hee Chang, Weiguo Zhang, William E. Fogler, John L. Magnani, Mahesh Basyal, Michael Andreeff, Lauren B Ostermann
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Acute myeloid leukemia (AML) is an aggressive heterogeneous hematologic disease with high mortality in patients older than 60 years. Clinical studies have proven that combinations of FDA-approved Bcl-2 inhibitor, venetoclax and hypomethylating agents
Publikováno v:
Blood. 136:17-17
Background: In sickle cell disease (SCD), recurrent episodes of vaso-occlusive crisis (VOC) contribute to morbidity and accelerated mortality. Analysis of the RESET Phase 3 study demonstrated that administration of the pan-selectin inhibitor, rivipan
Autor:
John L. Magnani, Vince Deng, David Stewart, Simone Daminelli, William E. Fogler, Adrian R. Carr, Michael Jarman
Publikováno v:
Cancer Research. 80:5867-5867
E-selectin is a cell adhesion glycoprotein expressed on endothelial cells and participates in the development of environmental-mediated drug resistance and poor clinical outcome in cancer. The E-selectin antagonist, uproleselan, interrupts leukemic c